Zobrazeno 1 - 10
of 179
pro vyhledávání: '"Shantaram S Joshi"'
Autor:
Don W. Coulter, Yashpal S. Chhonker, Devendra Kumar, Varun Kesherwani, Wafaa N. Aldhafiri, Erin M. McIntyre, Gracey Alexander, Sutapa Ray, Shantaram S. Joshi, Rongshi Li, Daryl J. Murry, Nagendra K. Chaturvedi
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-16 (2024)
Abstract Background Medulloblastoma (MB) patients with MYC oncogene amplification or overexpression exhibit extremely poor prognoses and therapy resistance. However, MYC itself has been one of the most challenging targets for cancer treatment. Here,
Externí odkaz:
https://doaj.org/article/1f0fbd593c6a46b394d3ab29ce868b00
Autor:
Amit K Mittal, Nagendra K Chaturvedi, Rae A Rohlfsen, Payal Gupta, Avadhut D Joshi, Ganapati V Hegde, R Gregory Bociek, Shantaram S Joshi
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e70352 (2013)
Earlier, we reported that CTLA4 expression is inversely correlated with CD38 expression in chronic lymphocytic leukemia (CLL) cells. However, the specific role of CTLA4 in CLL pathogenesis remains unknown. Therefore, to elucidate the possible role of
Externí odkaz:
https://doaj.org/article/3ebf534eacfa42628eafca56b4f52f16
Autor:
Simanta Pathak, Shibin Ma, Long Trinh, James Eudy, Kay-Uwe Wagner, Shantaram S Joshi, Runqing Lu
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e22628 (2011)
Interferon regulatory factor 4 (IRF4) is a critical transcriptional regulator in B cell development and function. We have previously shown that IRF4, together with IRF8, orchestrates pre-B cell development by limiting pre-B cell expansion and by prom
Externí odkaz:
https://doaj.org/article/68deff1a61ed4f019aff9b479ad85fc5
Autor:
Matthew J. Kling, Varun Kesherwani, Nitish K. Mishra, Gracey Alexander, Erin M. McIntyre, Sutapa Ray, Kishore B. Challagundla, Shantaram S. Joshi, Don W. Coulter, Nagendra K. Chaturvedi
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-14 (2022)
Abstract Background Medulloblastoma (MB) patients with MYC oncogene amplification or overexpression exhibit extremely poor clinical outcomes and respond poorly to current therapies. Epigenetic deregulation is very common in MYC-driven MB. The bromodo
Externí odkaz:
https://doaj.org/article/74ff7cb36dd04e48ba6d2bd841e3e5f5
Autor:
Matthew J. Kling, Connor N. Griggs, Erin M. McIntyre, Gracey Alexander, Sutapa Ray, Kishore B. Challagundla, Shantaram S. Joshi, Don W. Coulter, Nagendra K. Chaturvedi
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background Neuroblastoma (NB) patients with MYCN amplification or overexpression respond poorly to current therapies and exhibit extremely poor clinical outcomes. PI3K-mTOR signaling-driven deregulation of protein synthesis is very common in
Externí odkaz:
https://doaj.org/article/1e0bff91543c41f7aa95510776436cfe
Autor:
Varun Kesherwani, Mamta Shukla, Don W. Coulter, J. Graham Sharp, Shantaram S. Joshi, Nagendra K. Chaturvedi
Publikováno v:
BMC Medical Genomics, Vol 13, Iss 1, Pp 1-14 (2020)
Abstract Background Medulloblastoma (MB) is one of the most common malignant cancers in children. MB is primarily classified into four subgroups based on molecular and clinical characteristics as (1) WNT (2) Sonic-hedgehog (SHH) (3) Group 3 (4) Group
Externí odkaz:
https://doaj.org/article/aebfab7e45d04559b079a0f1131a8fd5
Autor:
Shantaram S. Joshi, Julie M. Vose, Amarnath Natarajan, Gordon L. Todd, Prakash Radhakrishnan, Ashima Shukla, Rajkumar N. Rajule, Nagendra K. Chaturvedi
PDF file - 52 KB, IC50 of 13-197 in different MCL cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fda1f90c6dd14e451ea67afc7152ea9
https://doi.org/10.1158/1535-7163.22498132.v1
https://doi.org/10.1158/1535-7163.22498132.v1
Autor:
Shantaram S. Joshi, Julie M. Vose, Amarnath Natarajan, Gordon L. Todd, Prakash Radhakrishnan, Ashima Shukla, Rajkumar N. Rajule, Nagendra K. Chaturvedi
Mantle cell lymphoma (MCL) is one of the most aggressive B-cell non-Hodgkin lymphomas with a median survival of approximately five years. Currently, there is no curative therapy available for refractory MCL because of relapse from therapy-resistant t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b99e3e1eca9bddecb93ab75760bf19a
https://doi.org/10.1158/1535-7163.c.6535801.v1
https://doi.org/10.1158/1535-7163.c.6535801.v1
Autor:
Shantaram S. Joshi, Julie M. Vose, Amarnath Natarajan, Gordon L. Todd, Prakash Radhakrishnan, Ashima Shukla, Rajkumar N. Rajule, Nagendra K. Chaturvedi
PDF file - 633 KB, Figure S1: Effect of 13-197 on the viability of normal B (nB) cells. Figure S2: Constitutive activation of NF-kB and mTOR pathway in different MCL cells. Figure S3: Effect of 13-197 on the activation of mTOR pathway molecules.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34812622873364f25f4a0011d92531e5
https://doi.org/10.1158/1535-7163.22498135
https://doi.org/10.1158/1535-7163.22498135
Autor:
Don W. Coulter, Shantaram S. Joshi, Hamid Band, J. Graham Sharp, Timothy R. McGuire, Yutong Liu, Sutapa Ray, Erin M. McIntyre, Mamta Shukla, Varun Kesherwani, Connor N. Griggs, Matthew J. Kling, Nagendra K. Chaturvedi
1. Immunohistochemistry (IHC). 2.Histological (H&E) analysis of cerebellar tumors. 3.Magnetic resonance imaging (MRI).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46288832035d349411e4e8e505f0fc34
https://doi.org/10.1158/1535-7163.22521717.v1
https://doi.org/10.1158/1535-7163.22521717.v1